Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SKIN vs VTAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SKIN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–4 Matrix Metrics)

SKIN Overall Winner 6-Pillar Tally: SKIN 6 – 0 VTAK Matrix Metrics: SKIN 6 – 4 VTAK

As of Nov 16, 2026, The Beauty Health Company (SKIN) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin).

  • Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. SKIN 34.1/100 SELL), SKIN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (2.4% vs. -388.1% operating margin) and revenue trajectory (-2.1% vs. +380.7% YoY).
  • Technical & Structure Timing Caution: SKIN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 69.8); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SKIN vs VTAK
SKIN NASDAQ Head-to-Head Winner
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (315.4% over 20 days), RSI 70
RSI-14: 69.8 · SMA20: $12.52 · SMA50: $6.25
VTAK NYSE American
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21

6-Pillar Scorecard Institutional Category Breakdown (SKIN 6 – 0 VTAK)

Columns: Metric · SKIN · VTAK
1. Valuation Multiples SKIN
Forward P/E 106.4x N/M
Trailing P/E 106.4x N/M
PEG Ratio 0.93x N/M
EV / Revenue 0.9x 0.3x
2. Growth & Scale SKIN
Revenue Growth (YoY) -2.1% +380.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $289M $1.9M
Market Cap $106.3M $548,639
3. Profitability & Quality SKIN
Gross Margin 67.2% 47.7%
Operating Margin 2.4% -388.1%
Net Profit Margin -6.3% 0.0%
Return on Equity (ROE) -30.1% -111.3%
4. Balance Sheet & Cash Flow SKIN
Cash Generation (TTM) $17M -$10M EBITDA
Cash Flow Margin 5.8% N/A
Net Cash / Leverage $161M Net Debt (6.61x D/E) $4.87 Book/Sh · -111.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SKIN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 517.4% (100th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 64.8% of Rev ($187M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Household & Personal Products Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SKIN (6) vs VTAK (4)
Institutional Metric SKIN VTAK Criterion Row Edge
Market Capitalization
Scale
$106.3M $548,639 Larger Scale SKIN
Trailing P/E Ratio
Valuation
106.4x N/M Lower Multiple SKIN
Forward P/E Ratio
Valuation
106.4x N/M Lower Multiple SKIN
Revenue Growth (YoY)
Growth
-2.1% +380.7% Higher Growth VTAK
Operating Margin (TTM)
Profitability
2.4% -388.1% Higher Margin SKIN
Net Profit Margin
Profitability
-6.3% 0.0% Higher Margin VTAK
Return on Equity (ROE)
Capital Efficiency
-30.1% -111.3% Higher ROE SKIN
52-Week Range Position
Momentum
83% ($0–$18) 1% ($0–$3) Stronger Trend SKIN
Beta / 30D Volatility
Risk Regime
-14.22β · 192% Vol 0.19β · 76% Vol Lower Realized Risk VTAK
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 58.1 / 100 (HOLD) Higher Composite VTAK
Trailing 12M Revenue (USD)
Operating Scale
$289M $1.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.2% 47.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.93x PEG · 0.9x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17M ($161M Net Debt (6.61x D/E)) -$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +13.88 pp
SKIN: -10.88% · VTAK: -24.76%
3M Horizon SKIN +63.74 pp
SKIN: -16.55% · VTAK: -80.29%
6M Horizon SKIN +53.36 pp
SKIN: -30.4% · VTAK: -83.76%
1Y Horizon SKIN +41.09 pp
SKIN: -51.54% · VTAK: -92.63%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SKIN Revenue VTAK Revenue SKIN Op. Margin VTAK Op. Margin Margin Leader
FY2018 N/A $10M N/A -498.0% VTAK
FY2019 $170M $10M 8.1% -801.9% SKIN
FY2020 $120M $0M -14.4% -13668.3% SKIN
FY2021 $260M $0M -15.4% -133027.3% SKIN
FY2022 $370M $0M -7.1% -192578.6% SKIN
FY2023 $400M $0M -32.9% -17674.0% SKIN
FY2024 $330M $0M -20.3% -2676.9% SKIN
FY2025 $300M $0M -6.9% -2581.6% SKIN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SKIN vs VTAK Key Questions & Quantitative Answers

As of Nov 16, 2026, The Beauty Health Company (SKIN) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin). Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. SKIN 34.1/100 SELL), SKIN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (2.4% vs. -388.1% operating margin) and revenue trajectory (-2.1% vs. +380.7% YoY). Technical & Structure Timing Caution: SKIN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 69.8); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SKIN leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with VTAK at +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SKIN cumulative revenue shifted +76.5% while VTAK shifted +0.0%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTAK.

SKIN screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus VTAK (-111.3% ROE) capital efficiency.

In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.